Associations between blood type and COVID-19 infection, intubation, and death.
Zietz M, Zucker J, Tatonetti NP. · 2020
Read Associations between blood type and COVID-19 infection, intubation, and death. by Zietz M, Zucker J, Tatonetti NP. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7666188.txt.
Introduction
Zietz and co-authors test whether blood type tracks with COVID-19 risk. They used health records from the New York Presbyterian hospital system. The set held 14,112 people tested for SARS-CoV-2 whose blood type was known. Outcomes were infection, intubation, and death.
Infection was a bit more common in non-O blood types than in type O. Risk of intubation fell for type A and rose for types AB and B. Death risk rose for type AB and fell for types A and B. Rh-negative type looked protective across all three outcomes. The authors add this to growing signs that blood type plays a role.
Catalog record
| CREATOR | Zietz M, Zucker J, Tatonetti NP. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Associations between blood type and COVID-19 infection, intubation, and death By Michael Zietz, Jason Zucker, Nicholas P. Tatonetti Published in: Nature Communications DOI: 10.1038/s41467-020-19623-x ABSTRACT The rapid global spread of the novel coronavirus SARS-CoV-2 has strained healthcare and testing resources, making the identification and prioritization of individuals most at-risk a critical challenge. Recent evidence suggests blood type may affect risk of severe COVID-19. Here, we use observational healthcare data on 14,112 individuals tested for SARS-CoV-2 with known blood type in the New York Presbyterian (NYP) hospital system to assess the association between ABO and Rh blood types and infection, intubation, and death. We find slightly increased infection prevalence among non-O types. Risk of intubation was decreased among A and increased among AB and B types, compared with type O, while risk of death was increased for type AB and decreased for types A and B. We estimate Rh-negative blood type to have a protective effect for all three outcomes. Our results add to the growing body of evidence suggesting blood type may play a role in COVID-19. INTRODUCTION The novel Coronavirus disease (COVID-19, caused by the SARS-CoV-2 virus) has spread rapidly across the globe and has caused over 21.1 million confirmed infections and over 761,000 deaths worldwide as of August 17, 20201. Within the United States, New York suffered among the worst outbreaks during the early phases of the pandemic. As of August 22, New York City has recorded 228,144 confirmed infections and 19,014 deaths2. A number of risk factors for COVID-19 morbidity and mortality are known, including age, sex, smoking, hypertension, diabetes, and chronic cardiovascular and respiratory diseases3,4. Recent work has demonstrated an association between ABO blood types and COVID-19 risk. Using data from Wuhan and Shenzhen, Zhao et al. found a greater proportion of A and a lower proportion of O blood types among COVID-19 patients, relative to the general populations of Wuhan and Shenzhen5. Similarly, using a meta-analysis of data from Italy and Spain, Ellinghaus et al. found6 a higher risk of COVID-19 among A and a lower risk among O blood types. Conversely, however, they estimated lower odds of mechanical ventilation for all non-O types, though the estimated odds ratios were not statistically significant at the 5% level for this outcome. The ABO blood type trait reflects polymorphisms within the ABO gene. This gene is associated with a number of other traits, including risk factors for COVID-19 morbidity and mortality. For example, genome-wide association studies have associated variants within ABO to activity of the angiotensin converting enzyme7, red blood cell count, hemoglobin concentration, hematocrit8–11, von Willebrand factor12–15, myocardial infarction16,17, coronary artery disease17–21, ischemic stroke13,19,22, type 2 diabetes23–25, and venous thromboembolism26–33. A 2012 meta-analysis found that, in addition to individual variants, a non-O blood type is among the most important genetic risk factors for venous thromboembolism34. These conditions are also relevant for COVID-19. For example, coagulopathy is a common issue for COVID-19 patients35–41, and risk of venous thromboembolism must be carefully managed42. The numerous associations between conditions and both blood type and COVID-19 provide reason to believe that true associations may exist between blood type and morbidity and mortality due to COVID-19. In addition, previous work has identified associations between ABO blood groups and a number of different infections or disease severity following infections, including SARS-CoV-143, P. falciparum44, H. pylori45, Norwalk virus46, hepatitis B virus47, and N. gonorrhoeae48. Rh(D) phenotypes (positive and negative Rh blood types) are associated with very few diseases compared to ABO49. Like ABO, Rh type is important for type compatibility and immune response. For example, hemolytic disease of the newborn is a concern when Rh(D) is mismatched between mother and offspring50. Other studies have found evidence that Rh-positive individuals are protected against the effects of latent toxoplasmosis51, though Toxoplasma gondii is a eukaryotic parasite52, not a virus like SARS-CoV-2. In this study, we sought to understand the association between SARS-CoV-2 infection/COVID-19 and blood type using electronic health record (EHR) data from NewYork-Presbyterian/Columbia University Irving Medical Center (NYP/CUIMC) hospital in New York City, USA. We compared both ABO and Rh(D) blood types, and we investigated initial infection status and two severe COVID-19 outcomes: intubation and death. We evaluated potential confounding due to population stratification using a multivariate analysis, and we report clinically meaningful measures of effect. RESULTS Data collection and cohort selection We determined blood types using laboratory measurements recorded in the NYP/CUIMC EHR system. After removing likely errors, such as individuals with contradictory blood-type results, we identified 14,112 adult individuals with known blood types who received at least one SARS-CoV-2 swab test (Table 1 and Supplementary Fig. 1). We performed chi-squared tests of independence and found insufficient evidence to conclude that the blood-group frequencies differ between SARS-CoV-2-tested and non-tested groups (Supplementary Table 1). Individuals were considered initially SARS-CoV-2-positive (COV+) if they tested positive on their first recorded test or within the following 96 h. We evaluated associations between blood types and outcomes using three comparisons: infection prevalence among initial tests and survival analysis for intubation and death among individuals with infections confirmed by the swab test. We report on clinical data as of August 1, 2020.Table 1Summary demographics for SARS-CoV-2-tested individuals at NYP/CUIMC, stratified by blood type.AABBORh negRh posN4298 (32.9)559 (4.3)2033 (15.6)6161 (47.2)1195 (9.2)11,856 (90.8)Age (IQR)58 (37–72)57 (37–71)57 (37–72)55 (36–71)56 (37–70)56 (37–71)Male (%)1676 (39.0)231 (41.3)778 (38.3)2339 (38.0)430 (36.0)4594 (38.7)Hispanic (%)1572 (36.6)173 (30.9)666 (32.8)2583 (41.9)389 (32.6)4605 (38.8)Race Asian (%)71 (1.7)21 (3.8)89 (4.4)123 (2.0)16 (1.3)288 (2.4) Black (%)629 (14.6)95 (17.0)493 (24.2)1179 (19.1)151 (12.6)2245 (18.9) Missing (%)728 (16.9)79 (14.1)370 (18.2)1093 (17.7)192 (16.1)2078 (17.5) Other (%)1085 (25.2)132 (23.6)464 (22.8)1715 (27.8)263 (22.0)3133 (26.4) White (%)1785 (41.5)232 (41.5)617 (30.3)2051 (33.3)573 (47.9)4112 (34.7)Outcomes Initially COV+ (%)754 (17.5)88 (15.7)363 (17.9)1060 (17.2)164 (13.7)2101 (17.7) COV+ (%)786 (18.3)94 (16.8)392 (19.3)1122 (18.2)175 (14.6)2219 (18.7) COV+ Intubated (%)111 (2.6)17 (3.0)78 (3.8)193 (3.1)24 (2.0)375 (3.2) COV+ Died (%)104 (2.4)15 (2.7)46 (2.3)166 (2.7)11 (0.9)320 (2.7)N is the number of individuals having the given blood type who had at least one recorded test for SARS-CoV-2. Age is reported as the median and interquartile range (25–75). Percents are reported relative to individuals having the blood type, except the N row, where percents are by blood-group type (ABO or Rh) and are relative to all individuals in the study. Infection prevalence The unadjusted prevalence of initial infection was higher among A and B blood types and lower among AB types, compared with type O (Table 2 and Fig. 1). To avoid bias with respect to healthcare utilization, length of hospital stay, and potential in-patient infection, we evaluated the prevalence of infection among individuals only during the first encounters in which they were tested. In addition, to account for the considerable risk of false-negative tests53,54 and the fact that providers would repeat the test in patients with high clinical suspicion for COVID-1955, any positive test during the first 96 h of an encounter was considered evidence of initial infection.Table 2Effect size estimates for blood types with and without correction for race and ethnicity.UnadjustedRace and ethnicity adjustedOutcomeBlood typeRiskRisk differenceRisk ratioRiskRisk differenceRisk ratioPrevalenceA17.5 (16.3–18.8)0.3 (−1.2–1.9)1.02 (0.93–1.12)18.0 (16.8–19.2)1.3 (−0.3–3.0)1.08 (0.98–1.19)AB15.7 (12.8–18.7)−1.5 (−4.5–1.7)0.91 (0.74–1.10)16.8 (13.9–19.8)0.1 (−2.8–3.2)1.01 (0.83–1.20)B17.9 (16.1–19.5)0.7 (−1.4–2.6)1.04 (0.92–1.16)18.0 (16.3–19.7)1.3 (−0.7–3.3)1.08 (0.96–1.20)O17.2 (16.2–18.1)ReferenceReference16.7 (15.7–17.6)ReferenceReferenceRh pos17.7 (17.0–18.4)ReferenceReference17.6 (16.9–18.3)ReferenceReferenceRh neg13.7 (11.8–15.5)−4.0 (−6.1 to −2.0)0.77 (0.66–0.88)14.9 (13.0–16.8)−2.7 (−4.7 to −0.8)0.85 (0.73–0.96)IntubationA17.2 (14.2–20.1)−3.2 (−7.5–0.3)0.84 (0.66–1.02)17.3 (14.3–20.4)−2.9 (−7.2–0.6)0.85 (0.68–1.03)AB21.8